Skip to main content
. 2015 Feb 20;50(2):139–151. doi: 10.1310/hpj5002-139

Table 2. Select gastrointestinal adverse effects during a 52-week safety assessment period of a phase 3 trial33.

Adverse effect Ferric citrate (n = 289) Active control (n = 149)
Diarrhea 25.6% 14.1%
Fecal discoloration 17% 0%
Nausea 14.2% 14.1%
Vomiting 9% 14.8%
Constipation 8% 5.4%
Abdominal pain 6.2% 6%